Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice

World Journal of Gastroenterology

Volumn 14, Issue 22, 2008, Pages 3554-3562

  Zhang, Dan Ying ^a   Shen, Xi Zhong ^a   Wang, Ji Yao ^a   Dong, Ling ^a   Zheng, Yong Li ^a   Wu, Li Li ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

5 fluorouracil; Chitosan; Gastric carcinoma; Nanoparticles; Polyaspartic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CHITOSAN; CREATININE; FLUOROURACIL; NANOPARTICLE; POLYASPARTIC ACID; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BLOOD TOXICITY; CANCER INHIBITION; COLONY FORMING UNIT GM; DOWN REGULATION; DRUG RELEASE; HISTOPATHOLOGY; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NUDE MOUSE; STOMACH CARCINOMA; TUMOR VOLUME; UPREGULATION;

EID: 54349097782     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3554     Document Type: Article

References (32)

1. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest Neut Drugs 2000; 18: 299-313
2. Llorca Ferrandiz C, Esquerdo Galiana G, Cervera Grau JM, Briceo, Garcia HC, Calduch Broseta JV, Del Pino Cuadrado J. [5-Fluorouracil-induced small bowel toxicity in a patient with colorectal cancer] Clin Transl Oncol 2005; 7: 356-357
3. Saif MW. Capecitabine versus continuous-infusion 5-fluoroutacil for colorectat cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer 2005; 5: 89-100
4. Diasio RB, Johnson MR. T4e role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000; 61: 199-203
5. Ogawa K, Yui T, Okuyama K. Three D structures of chitosan. Int J Biol Macromol 2004; 34: 1-8
6. Prabaharan M, Mano IF. Chitosan-based particles as controlled drug delivery systems. Drug Deliv 2005; 12: 41-57 7 Aspden TJ, Mason JDT, Jones NS. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucocitiary transport rates in human turbinates and volunteers. J Pharm Sci 1997; 86: 509-513
7. Chornet E, Dumitriu S. Inclusion and release of proteins from polysaccharide-based polyion complexes. Adv Drug Deliv Rev 1998; 31: 223-246
8. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 1996; 13: 896-901
9. Park SB, You JO, Park HY, Haam SJ, Kim WS. A novel pH-sensitive membrane from chitosan-TEOS IPN; preparation and its drug permeation characteristics. Biomaterials 2001; 22: 323-330
10. Mi FL, Wu YB, Shyu SS, Schoung JY, Huang YB, Tsai YH, Hao JY. Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. J Biomed Mater Res 2002; 59: 438-449
11. Shahidi F, Abuzaytoun R. Chitin, chitosan, and co-products: chemistry, production, applications, and health effects. Adv Food Nutr Res 2005; 49: 93-135
12. Tang ES, Huang M, Lim LY. Ultrasonication of chitosan and chitosan nanoparticles. Int J Pharm 2003; 265: 103-114
13. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonzo MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release 2001; 73: 255-267
14. Wu LL, Zheng YL, Shen XZ, Fu SK, Dong L. Pharmacokinetics of Chitosan-Polyaspartic acid-5Fluorouracil Nanoparticles in vitro. Fudan Univ J Med Sci 2006; 33(6): 757-760
15. Nakato T, Kusuno A, Kakudii T. Synthesis of poly (succinimide) by bulk polycondensation of L-aspartic acid with an acid catalyst. Polym Sci Pol Chem 2000; 38: 117-122
16. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. Journal of Applied Polymer Science 1997; 63: 125-132
17. Chu B, Wang Z, Yu J. Dynamic light scattering study of internal motions of polymer coils in dilute solution. Macromolecules 1991; 24: 6832-6838
18. Moehler M, Teufel A, Galle PR. New chemotherapeutic strategies in colorectal cancer. Recent Results Cancer Res 2005; 165: 250-259
19. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T, Tsujihara K. Complete regression of xenografted human carcinomas by camptothecin ana-logue carboxymethyl dextran conjugate (T-0128). Cancer Research 2000; 60: 2988-2995
20. Kuwata T, Wang IM, Tamura T, Ponnamperuma RM, Levine R, Holmes KL, Morse HC, De Luca LM, Ozato K. Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood 2000; 95: 3349-3356
21. Jenkins WT, Evans SM, Koch CJ. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int J Radiat Oncol Biol Phys 2000; 46: 1005-1017
22. Chu E, Drake JC, Koeller DM, Zinn S, Jamis-Dow CA, Yeh GC, Allegra CJ. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 1991; 39: 136-143
23. Desai MP, Labhasetwar V, Amidon GL, Levy RJ, Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13: 1838-1845
24. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel I. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000; 50: 147-160
25. Zheng Y, Wu Y, Yang W, Wang C, Fu S, Shen X. Preparation, characterization, and drug release in vitro of chitosan-glycyrrhetic acid nanoparticles. J Pharm Sci 2006; 95: 181-191
26. Wu Y, Yang WL, Wang CC, Hu JH, Fu SK. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm 2005; 295: 235-245
27. Tauro JR, Gemeinhart RA. Development of amine-containing polymeric particles. J Biomater Sci Polym Ed 2005; 16: 1233-1244
28. Ehtezazi T, Govender T, Stolnik S. Hydrogen bonding and electrostatic interaction contributions to the interaction of a cationic drug with polyaspartic acid. Pharm Res 2000; 17: 871-878
29. Jiang HL, Zhu KJ. Comparison of poly(aspartic acid) hydrogel and poly(aspartic acid)/gelatin complex for entrapment and pH-serisitive release of protein drugs. J Appl Polymer Sci 2006; 9: 2320-2329
30. Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R, Merlin JL. Bcl-2/Box protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 2000; 83: 1380-1386
31. Sawa H, Kobayashi T, Mukai K, Zhang W, Shiku H. Bax overexpression enhances cytochrome e release from mitochondria and sensitizes KA IOIII gastric cancer cells to chemotherapeutic agent-induced apoptosis. Int J Oncol 2000; 16: 745-749
32. Kawakami K, Tsukuda M, Mizano H, Nishimura G, Ishii A, Hamajima K. Alteration of the Bcl-2/Bax status of head and heck cancer cell lines by chemotherapeutic agents. Anticancer Res 1999; 19: 3927-3932